The SARS Patent Coup Explained - Dr. David Martin

Dr. Martin explains how the coronavirus gained an illegal patent probably though bribing key patent office officials.

=============================

Coronavirus isolated from humans
Discloses herein is a newly isolated human coronavirus 7220852 (2007)
https://www.lens.org/lens/patent/025-713-694-175-515/fulltext

Coronavirus isolated from humans
Patent US 7220852 B1 Granted Patent Family: 2s / 2ex Family Jurisdictions: US Legal Status: Inactive
Application No: 82290404 Filed: Apr 12, 2004 Published: May 22, 2007 Earliest Priority: Apr 25, 2003 Granted: May 22, 2007

Owners: The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services Centers for Disease Control and Prevention

Applicants: Us Health
Inventors: Rota Paul A , Anderson Larry J , Bellini William J , Burns Cara Carthel , Campagnoli Raymond , Chen Qi , Comer James A , Emery Shannon L , Erdman Dean D , Goldsmith Cynthia S , Humphrey Charles D , Icenogle Joseph P , Ksiazek Thomas G , Monroe Stephan S , Nix William Allan , Oberste M Steven , Peret Teresa C T , Rollin Pierre E , Pallansch Mark A , Sanchez Anthony Tong Suxiang , Zaki Sherif R Show Less...

Abstract
Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.

=============================
US Patent 7776521 (2007)

Coronavirus isolated from humans
https://patents.google.com/patent/US7776521B1/en

Abstract
Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.

=============================

US Patent US7279327B2
https://patents.google.com/patent/US7279327B2/en

Methods for producing recombinant coronavirus

Abstract
A helper cell for producing an infectious, replication defective, coronavirus (or more generally nidovirus) particle cell comprises (a) a nidovirus permissive cell; (b) a nidovirus replicon RNA comprising the nidovirus packaging signal and a heterologous RNA sequence, wherein the replicon RNA further lacks a sequence encoding at least one nidovirus structural protein; and (c) at least one separate helper RNA encoding the at least one structural protein absent from the replicon RNA, the helper RNA(s) lacking the nidovirus packaging signal. The combined expression of the replicon RNA and the helper RNA in the nidovirus permissive cell produces an assembled nidovirus particle which comprises the heterologous RNA sequence, is able to infect a cell, and is unable to complete viral replication in the absence of the helper RNA due to the absence of the structural protein coding sequence in the packaged replicon. Compositions for use in making such helper cells, along with viral particles produced from such cells, compositions of such viral particles, and methods of making and using such viral particles, are also disclosed.

=============================
"Heterologous" - Smoking gun for weaponized virus https://en.wikipedia.org/wiki/Heterologous

In cell biology and protein biochemistry, heterologous expression means that a protein is experimentally put into a cell that does not normally make (i.e., express) that protein.[1] Heterologous (meaning 'derived from a different organism') refers to the fact that often the transferred protein was initially cloned from or derived from a different cell type or a different species from the recipient.

Typically the protein itself is not transferred, but instead the 'correctly edited'[2] genetic material coding for the protein (the complementary DNA or cDNA) is added to the recipient cell. The genetic material that is transferred typically must be within a format that encourages the recipient cell to express the cDNA as a protein (i.e., it is put in an expression vector).

Methods for transferring foreign genetic material into a recipient cell include transfection and transduction. The choice of recipient cell type is often based on an experimental need to examine the protein's function in detail, and the most prevalent recipients, known as heterologous expression systems, are chosen usually because they are easy to transfer DNA into or because they allow for a simpler assessment of the protein's function.